208 related articles for article (PubMed ID: 9565163)
1. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
2. The manufacturing process for recombinant factor IX.
Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of recombinant factor IX.
White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of recombinant factor IX.
Bond M; Jankowski M; Patel H; Karnik S; Strang A; Xu B; Rouse J; Koza S; Letwin B; Steckert J; Amphlett G; Scoble H
Semin Hematol; 1998 Apr; 35(2 Suppl 2):11-7. PubMed ID: 9565161
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of recombinant factor IX.
Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
[TBL] [Abstract][Full Text] [Related]
6. Viral safety of B-domain deleted recombinant factor VIII.
Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
[TBL] [Abstract][Full Text] [Related]
7. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
9. The formulation of recombinant factor IX: stability, robustness, and convenience.
Bush L; Webb C; Bartlett L; Burnett B
Semin Hematol; 1998 Apr; 35(2 Suppl 2):18-21. PubMed ID: 9565162
[TBL] [Abstract][Full Text] [Related]
10. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
12. Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.
Enjolras N; Dargaud Y; Pérot E; Guillaume F; Becchi M; Négrier C
Thromb Res; 2012 Nov; 130(5):e266-73. PubMed ID: 23021500
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
Poon MC; Lillicrap D; Hensman C; Card R; Scully MF
Thromb Haemost; 2002 Mar; 87(3):431-5. PubMed ID: 11916075
[TBL] [Abstract][Full Text] [Related]
14. [Current treatment of hemophilia B].
Tusell JM
Sangre (Barc); 1997 Oct; 42(5):401-6. PubMed ID: 9424742
[No Abstract] [Full Text] [Related]
15. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Pollmann H
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
[TBL] [Abstract][Full Text] [Related]
16. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Turecek PL; Abbühl B; Tangada SD; Chapman M; Gritsch H; Rottensteiner H; Schrenk G; Mitterer A; Dietrich B; Höllriegl W; Schiviz A; Horling F; Reipert BM; Muchitsch EM; Pavlova BG; Scheiflinger F
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):163-77. PubMed ID: 25660348
[TBL] [Abstract][Full Text] [Related]
17. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
Adamson SR
Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
[TBL] [Abstract][Full Text] [Related]
18. Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines.
Dadehbeigi N; Ostad SN; Faramarzi MA; Ghahremani MH
Biotechnol Lett; 2008 Nov; 30(11):1909-12. PubMed ID: 18581062
[TBL] [Abstract][Full Text] [Related]
19. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
20. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
Aledort LM
Semin Hematol; 1991 Jul; 28(3 Suppl 6):1-2. PubMed ID: 1780765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
